TCA’s Nine-Warning Ceiling: FDA Lacks Authority to Expand Cigarette Warning Statements Beyond Congress’s Enumerated List (and APA § 705 Postponement Operates Rule-Wide)

I. Introduction

Case: R J Reynolds Tobacco Company v. FDA
Court: United States Court of Appeals for the Fifth Circuit
Date: August 18, 2026

This appeal concerns whether the Food and Drug Administration (FDA), implementing the Family Smoking Prevention and Tobacco Control Act (TCA), may require cigarette manufacturers and retailers to display eleven rotating warning statements on packages and advertisements when Congress specified nine warning statements in 15 U.S.C. § 1333(a)(1). Multiple cigarette manufacturers and retailers (Plaintiffs—Appellees) challenged the FDA’s final graphic-warning rule under the Administrative Procedure Act (APA) and the First Amendment.

The litigation’s posture is critical: the Fifth Circuit reviewed only the district court’s interim postponement of the Rule’s effective date under APA § 705 while merits litigation continues on remand. The panel framed the dispute as an “opposite problem” from broad delegations: Congress legislated precisely (nine warnings), and the agency treated that precision as optional (eleven warnings).

The key issues were:

  • Statutory authority: Whether § 1333(a)(1) creates an exhaustive (“closed”) set of nine warnings and whether the FDA may add to it via § 1333(d)[2] or § 1334(a).
  • Interim relief factors: Likelihood of success, irreparable harm, balance of equities, and public interest.
  • Remedy scope: Whether § 705 relief is limited to the parties or operates rule-wide, and whether Trump v. CASA, Inc. constrains the remedy.
  • Severability: Whether the court should sever invalid parts and allow the rest to take effect at the preliminary stage.

II. Summary of the Opinion

The Fifth Circuit affirmed the Eastern District of Texas’s postponement of the FDA Rule’s effective date. The panel held that the district court did not abuse its discretion in concluding Plaintiffs were substantially likely to succeed on their APA claim that the FDA exceeded statutory authority by requiring more than the nine warnings enumerated in § 1333(a)(1).

The court further held that:

  • Plaintiffs showed irreparable harm via unrecoverable compliance costs (sovereign immunity bars damages).
  • The equities and public interest favored maintaining the longstanding status quo pending judicial review.
  • APA § 705 postponement is rule-focused, not party-limited, and thus properly applies beyond the named Plaintiffs.
  • Trump v. CASA, Inc. does not restrict congressionally authorized statutory remedies under the APA.
  • Severability did not compel partial effectiveness at this preliminary posture and could not “manufacture” agency authority absent statutory authorization.

The panel emphasized the narrowness of its holding: it did not finally resolve all APA issues, and interim relief could rest on a substantial likelihood of success on even one claim.

III. Analysis

A. Precedents Cited

1. Tobacco-warning regulatory history and parallel litigation

  • R.J. Reynolds Tobacco Co. v. FDA, 96 F.4th 863 (5th Cir. 2024)
    Used as both regulatory backdrop (decades of warnings regulation) and procedural context: the Fifth Circuit previously reversed a First Amendment injunction, remanding for APA consideration. That history mattered because the court treated the present appeal as limited to interim relief pending merits review.
  • R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205 (D.C. Cir. 2012) and Am. Meat Inst. v. USDA, 760 F.3d 18 (D.C. Cir. 2014) (en banc)
    Cited to summarize why the FDA’s first (2011) attempt at graphic warnings failed. The Fifth Circuit did not revisit those First Amendment merits, but noted the FDA’s shift in stated purpose—from reducing smoking to “promot[ing] greater public understanding.”
  • Discount Tobacco City & Lottery, Inc. v. United States, 674 F.3d 509 (6th Cir. 2012)
    Mentioned to confirm the TCA’s broader constitutional survival in earlier challenges, setting the stage for today’s narrower question about the FDA’s statutory execution of Congress’s detailed warning scheme.
  • Philip Morris USA Inc. v. FDA, 801 F. Supp. 3d 1353 (S.D. Ga. 2025)
    Presented as a parallel, live challenge. The Georgia court vacated the Rule for a procedural notice-and-comment defect (data disclosure), while rejecting other authority and merits challenges. The Fifth Circuit distinguished that posture and underscored independent grounds: the Texas postponement rested on statutory numeric limits; the Georgia vacatur on procedure. The opinion openly noted the Georgia court’s different view that “changing the number of warnings is authorized by section 1334.”

2. Standards for interim relief and appellate review

  • Rest. L. Ctr. v. U.S. Dep't of Lab., 66 F.4th 593 (5th Cir. 2023)
    Supplied the four-factor test for interim injunctive relief applied via APA § 705.
  • Nken v. Holder, 556 U.S. 418 (2009)
    Cited for the proposition that when the government is a party, the “balance of equities” and “public interest” factors merge.
  • Texas v. United States, 809 F.3d 134 (5th Cir. 2015)
    Provided the abuse-of-discretion standard for reviewing interim relief.
  • Speaks v. Kruse, 445 F.3d 396 (5th Cir. 2006) and Anibowei v. Morgan, 70 F.4th 898 (5th Cir. 2023)
    Cited for de novo review of legal conclusions and clear-error review of factual findings.
  • Affinity Healthcare Servs. v. Sebelius, 720 F. Supp. 2d 12 (D.D.C. 2010) and Texas v. EPA, 829 F.3d 405 (5th Cir. 2016)
    Used to equate § 705 postponement with traditional interim injunction standards and to support the irreparable-harm proposition that unrecoverable compliance costs usually qualify.
  • Mock v. Garland, 75 F.4th 563 (5th Cir. 2023)
    Supported the panel’s approach of affirming interim relief based on a likelihood of success on a single claim without addressing all alternative claims.
  • ICEE Distributors, Inc. v. J&J Snack Foods Corp., 325 F.3d 586 (5th Cir. 2003) and Sampson v. Murray, 415 U.S. 61 (1974)
    Invoked to justify appellate reliance on the record even if district-court findings on some factors were brief.

3. Statutory interpretation and limits on agency power

  • Duncan v. Walker, 533 U.S. 167 (2001)
    Cited for the baseline rule: begin with statutory text.
  • United States v. Maturino, 887 F.3d 716 (5th Cir. 2018)
    Quoted for textual primacy (“the alpha and the omega” of interpretation).
  • Henson v. Santander Consumer USA Inc., 582 U.S. 79 (2017)
    Used to reinforce ordinary-meaning interpretation.
  • U.S. ex rel. Polansky v. Exec. Health Res. Inc., 599 U.S. 419 (2023), Nat'l Ass'n of Home Builders v. Defs. of Wildlife, 551 U.S. 644 (2007), and Hartford Underwriters Ins. Co. v. Union Planters Bank, N.A., 530 U.S. 1 (2000)
    Cited for the principle that courts do not infer “sweeping authority from silence,” and that Congress means what it says.
  • RadLAX Gateway Hotel, LLC v. Amalgamated Bank, 566 U.S. 639 (2012), Morales v. Trans World Airlines, Inc., 504 U.S. 374 (1992), and HCSC-Laundry v. United States, 450 U.S. 1 (1981)
    Provided the “specific governs the general” canon that the court applied in harmonizing § 1333 with § 1334.
  • Loper Bright Enters. v. Raimondo, 603 U.S. 369 (2024) and West Virginia v. EPA, 597 U.S. 697 (2022)
    Positioned the decision in the post-deference environment: agency statutory interpretations receive no deference as such, and agencies may not “rewrite statutes in the name of policy goals.” While the case is statutory, the court used these decisions to underscore judicial responsibility to enforce Congress’s precision.
  • Antonin Scalia & Bryan A. Garner, Reading Law: The Interpretation of Legal Texts
    Treated as persuasive interpretive authority on negative implication, “include” lists, surplusage, and harmonious-reading canons.

4. Irreparable harm from unrecoverable compliance costs

  • Wages & White Lion Invs., L.L.C. v. FDA, 16 F.4th 1130 (5th Cir. 2021)
    Key authority that sovereign immunity makes compliance costs unrecoverable and therefore often irreparable.
  • Ala. Ass'n of Realtors v. HHS, 594 U.S. 758 (2021) (per curiam), Rest. L. Ctr. v. U.S. Dep't of Lab., 66 F.4th 593 (5th Cir. 2023), and Thunder Basin Coal Co. v. Reich, 510 U.S. 200 (1994) (Scalia, J., concurring)
    Supported the proposition that regulated parties forced to spend unrecoverable sums under potentially unlawful regulation face irreparable injury.

5. APA remedies, nationwide effect, and “universal injunction” debates

  • Career Colls. & Schs. of Tex. v. U.S. Dep't of Educ., 98 F.4th 220 (5th Cir. 2024) and In re Clark, 94 F.4th 502 (5th Cir. 2024)
    These are pivotal to the Fifth Circuit’s remedial holding: § 705 postponement and § 706 vacatur are “not party-restricted” because they operate on the agency action itself, producing effects beyond the named parties.
  • Cargill v. Garland, 57 F.4th 447 (5th Cir. 2023) (en banc)
    Cited for the proposition that § 706 vacatur is the default remedy in the circuit, reinforcing action-centric (not party-centric) APA relief.
  • State v. Biden, 10 F.4th 538 (5th Cir. 2021) (quoting League of Women Voters of U.S. v. Newby, 838 F.3d 1 (D.C. Cir. 2016)) and BST Holdings, L.L.C. v. OSHA, 17 F.4th 604 (5th Cir. 2021)
    Used to frame public interest: there is generally no public interest in unlawful agency action; preventing it does not disserve the public interest.
  • Trump v. CASA, Inc., 606 U.S. 831 (2025)
    The FDA invoked CASA to argue against broad relief. The Fifth Circuit distinguished CASA as addressing only equitable universal injunctions—not APA statutory remedies—and noted CASA’s express carveout: it did not decide whether the APA authorizes vacatur (or § 705’s functional equivalent). The panel further referenced CASA’s footnote and concurrence recognizing APA “functional equivalents.”

6. Severability limits and “courts cannot rewrite agency rules”

  • Space Exploration Techs. Corp. v. NLRB, 151 F.4th 761 (5th Cir. 2025)
    Used to explain that severability does not preclude preliminary relief and that severability clauses triggered by “held to be invalid” may not apply at a postponement stage.
  • George v. McDonough, 596 U.S. 740 (2022) (quoting Dixon v. United States, 381 U.S. 68 (1965)) and FG Hemisphere Assocs., LLC v. Republique du Congo, 455 F.3d 575 (5th Cir. 2006)
    Cited for the idea that unauthorized regulation is a “nullity” and that lack of authority is not cured by later modifications.
  • SEC v. Chenery Corp., 318 U.S. 80 (1943)
    Anchored the court’s refusal to engage in judicial policymaking by selecting which FDA-created warnings should survive severance.

B. Legal Reasoning

1. The “closed set” reading of § 1333(a)(1): nine means nine

The panel’s statutory analysis is straightforwardly textual. Section 1333(a)(1) makes it unlawful to sell cigarettes if a package “fails to bear … one of the following labels,” and then Congress lists nine warnings. The court treated this formulation as a classic closed list: no “including,” no “such as,” and no textual signal that the list is illustrative. The FDA’s position—that the agency can require eleven warnings without an explicit “exactly nine” clause—was rejected as inconsistent with ordinary meaning and negative implication.

The court bolstered exclusivity with structural cross-references: multiple subsections refer back to the warnings “specified in subsection (a)(1),” and Congress’s rotation regime (§ 1333(c)) assumes a finite set whose distribution can be equalized and sequenced. Allowing a fluid set of agency-added warnings would, in the court’s view, disrupt the coherence of this rotation scheme.

2. “Adjust” authority in § 1333(d)[2] is modest, not creative

The FDA’s fallback was § 1333(d)[2], which permits the Secretary to “adjust” “format, type size, color graphics, and text” if the agency finds the change would “promote greater public understanding.” The panel treated “adjust” as a limiting verb: to modify an existing requirement, not to create additional warning statements or expand the enumerated set. Context mattered: the statute enumerates specific adjustable attributes but never mentions adjusting the “number” of warnings.

3. § 1334(a) (preemption) is not an independent delegation

The FDA argued that § 1334(a), as amended, authorizes “additional or different statements” and therefore expands FDA authority. The panel rejected this as a category error. It characterized § 1334 as a preemption provision allocating regulatory space between federal authority and state/local regulation. The “except to the extent” clause was read as presupposing valid authority “pursuant to” the TCA or specified FDCA provisions; it does not itself create substantive power.

The court’s reasoning relied on canons and statutory architecture:

  • Title/structure: § 1334 is titled “Preemption” and framed as a prohibition (“no statement … shall be required”), signaling it is not a freestanding grant.
  • Surplusage avoidance: reading § 1334(a) as an independent grant would risk nullifying § 1333(d)[2]’s conditions (including the “public understanding” finding).
  • Specific-over-general: § 1333 is the detailed, operative warning regime; § 1334’s general carveout cannot swallow § 1333’s precise limits.
  • Harmonious reading: § 1333 provides substantive authority and boundaries; § 1334 ensures those authorized federal requirements are not preempted.

The panel acknowledged that Philip Morris USA Inc. v. FDA read § 1334 differently (as affirmative authorization) but treated that divergence as insufficient to show the Texas district court’s reading was an abuse of discretion—especially given the preliminary posture.

4. Interim relief factors: irreparable harm and the status quo

The court affirmed the district court’s irreparable-harm finding largely on the unrecoverability of compliance costs: redesigning packaging and ads, retooling printing/distribution, and supply chain coordination. Because the FDA is shielded by sovereign immunity, the costs could not be recouped if the Rule is later invalidated—an archetypal irreparable injury in Fifth Circuit doctrine.

On equities and public interest, the panel emphasized that the Rule’s stated purpose was “public understanding,” not a time-sensitive reduction in smoking rates. Given the decades-long existence of textual warnings and the seventeen-year gap since the TCA’s enactment without any operative graphic-warning regime, the court concluded postponement preserved (rather than disrupted) the status quo. It reiterated a recurrent principle: the public is not served by enforcing a rule that likely exceeds statutory authority.

5. Remedy: § 705 postponement is action-centric; CASA does not shrink statutory APA relief

The panel treated the scope question as controlled by APA text and Fifth Circuit precedent. Section 705 authorizes postponing the effective date of an “agency action,” which the court read as action-centric rather than party-centric, echoing its approach to § 706’s “set aside” remedy.

The FDA’s CASA argument failed because CASA addressed only equitable universal injunctions and expressly left APA remedial questions open. The Fifth Circuit therefore held CASA does not constrain § 705 postponement. Even though the district court’s order used both “injunction” language and § 705 language, the panel read the injunction as implementing and reinforcing (not expanding) the § 705 postponement.

6. Severability: not a preliminary-stage mandate and not a cure for lack of authority

The court rejected the FDA’s severability push for two reasons:

  • Timing/trigger: the TCA severability clause applies when a provision “is held to be invalid”; a § 705 postponement is not a final invalidation.
  • Institutional competence: severing down to nine warnings would require choosing which of the FDA’s eleven survive; absent FDA guidance, this would violate SEC v. Chenery Corp. by having the court rewrite the rule or make policy choices for the agency.

C. Impact

1. Substantive constraint: enumerated warning statements are a statutory ceiling

The opinion’s principal doctrinal move is to treat § 1333(a)(1) as an exhaustive list that sets a hard numerical cap on warning statements. If this view persists on final merits (and survives any circuit conflict), it would sharply constrain the FDA’s ability to “modernize” cigarette warnings by expanding the set, limiting it to Congress’s nine statements and any permissible “adjustments” that do not functionally add new warnings.

2. Narrow but potent administrative-law signal in the post-deference era

By invoking Loper Bright Enters. v. Raimondo and West Virginia v. EPA, the panel framed the case as emblematic of a broader trend: courts will enforce statutory detail against agencies even where the agency argues a broader reading better serves public-health purposes. The opinion thus reads as a post-Chevron reaffirmation of textual constraint when Congress is specific.

3. Remedial significance: rule-wide § 705 postponements in the Fifth Circuit

On remedies, the decision reinforces the Fifth Circuit’s action-centric understanding of APA relief: § 705 postponements, like § 706 vacatur, are not naturally cabined to parties. This matters beyond tobacco regulation, because it provides a blueprint for regulated entities to seek rule-wide pauses pending merits review—without relying on the contested doctrine of universal injunctions.

4. Inter-court tension: § 1334(a) as authority vs. preemption carveout

The Fifth Circuit’s explicit disagreement with the Southern District of Georgia’s reading in Philip Morris USA Inc. v. FDA flags a developing fault line: whether the amended preemption clause (§ 1334(a)) can be read as an affirmative delegation to require “additional or different statements.” With the Eleventh Circuit appeal pending, the possibility of a circuit split (or at least divergent district-court outcomes) increases the odds of eventual Supreme Court review—especially given the economic and public-health stakes.

IV. Complex Concepts Simplified

  • “Closed list” / “one of the following”: When a statute says you must pick “one of the following” and then lists items, courts often treat that list as exhaustive—no extras allowed.
  • “Adjust” vs. “expand”: To “adjust” generally means to tweak what exists (size, format, wording), not to add more items to a congressionally fixed set.
  • Preemption: A preemption clause typically limits state/local regulation. It usually does not grant new federal regulatory power; it clarifies who is allowed to regulate and when.
  • APA § 705 postponement: A court can temporarily delay a rule’s effective date while the case is being reviewed—akin to a stay—so that regulated parties are not forced to comply before legality is decided.
  • Irreparable harm (sovereign immunity): If the government can’t be sued for money damages, businesses forced to spend money to comply with a rule often can’t recover those costs later—making the harm “irreparable.”
  • Vacatur vs. injunction: Vacatur (setting aside) targets the rule itself; an injunction typically targets the parties’ conduct. The Fifth Circuit treats APA remedies as operating on the agency action, not merely on the litigants.
  • Chenery principle: Courts cannot rewrite an agency rule to make it lawful; they review what the agency actually did and why it did it.

V. Conclusion

R J Reynolds Tobacco Company v. FDA establishes (at least at the interim-relief stage) a clear interpretive and remedial message: when Congress enumerates a fixed set of required cigarette warnings in § 1333(a)(1), the FDA likely cannot treat that number as optional by adding more warnings under the banner of “adjust[ing]” text or by repurposing § 1334(a)’s preemption language as a delegation. The decision also strengthens Fifth Circuit doctrine that APA § 705 postponements are rule-wide, and that Trump v. CASA, Inc. does not contract statutory APA remedies.

The broader significance lies in its insistence that agency implementation must match congressional precision—particularly in a post-Loper Bright landscape—while simultaneously reinforcing the Fifth Circuit’s action-centric approach to APA interim relief that pauses contested regulations across the board pending merits adjudication.